These observations are consistent with a recent case reported by Ozaki et al. [14], in which CRS following durvalumab and tremelimumab therapy for advanced HCC was accompanied by elevated levels of IL-6 and DAMPs, including HMGB1. Here, HMGB1 is linked to hepatocellular carcinoma.